8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 8, 2026·SEC
Material company update
Mar 30, 2026·SEC
Phio Pharmaceuticals Corp.(PHIO)Earnings, Financials & Key Ratios
PHIO•NASDAQ
Price updated Jun 19, 2026
AboutPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Show more
- Revenue$0
- EBITDA-$9M-24.8%
- Net Income-$9M-21.7%
- EPS (Diluted)-1.45-59.3%
- ROE-69.95%+39.1%
PHIO Key Insights
Phio Pharmaceuticals Corp. (PHIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PHIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PHIO Price & Volume
Phio Pharmaceuticals Corp. (PHIO) stock price & volume — 10-year historical chart
Loading chart...
PHIO Growth Metrics
Phio Pharmaceuticals Corp. (PHIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-61.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM100%
Return on Capital
10 Years-104.07%
5 Years-90.37%
3 Years-102.18%
Last Year-71.54%
PHIO Peer Comparison
Phio Pharmaceuticals Corp. (PHIO) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 |
Compare PHIO vs Peers
Phio Pharmaceuticals Corp. (PHIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHIO Income Statement
Phio Pharmaceuticals Corp. (PHIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 15K | 138K | 21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | -21.05% | 820% | -84.78% | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 5.37M | 4.33M | 0 | 3.72M | 8.89M | 7.01M | 6.33M | 3.64M | 0 | 1.07M |
COGS % of Revenue | 35800% | 3134.78% | - | - | - | - | - | - | - | - |
Gross Profit | -5.36M▲ 0% | -4.19M▲ 21.8% | 21K▲ 100.5% | -3.72M▼ 17795.2% | -8.89M▼ 139.1% | -7.01M▲ 21.1% | -6.33M▲ 9.7% | -3.64M▲ 42.5% | 0▲ 100.0% | -1.07M▲ 0% |
Gross Margin % | -35700% | -3034.78% | 100% | - | - | - | - | - | - | - |
Gross Profit Growth % | 0.76% | 21.79% | 100.5% | -17795.24% | -139.13% | 21.09% | 9.7% | 42.47% | 100% | - |
Operating Expenses | 9.38M | 7.5M | 9.01M | 5.08M | 4.63M | 4.45M | 4.49M | 3.74M | 9.22M | 10.44M |
OpEx % of Revenue | 62540% | 5436.23% | 42895.24% | - | - | - | - | - | - | - |
Selling, General & Admin | 4.01M | 3.18M | 4.71M | 5.08M | 4.63M | 4.45M | 4.29M | 3.74M | 4.6M | 4.99M |
SG&A % of Revenue | 26740% | 2301.45% | 22419.05% | - | - | - | - | - | - | - |
Research & Development | 5.37M | 4.33M | 4.3M | 3.72M | 8.89M | 7.01M | 6.33M | 3.64M | 4.62M | 6.53M |
R&D % of Revenue | 35800% | 3134.78% | 20476.19% | - | - | - | - | - | - | - |
Other Operating Expenses | 4.7M | 4K | 0 | -3.72M | -8.89M | -7.01M | -6.13M | -3.64M | 0 | -1000K |
Operating Income | -14.06M▲ 0% | -7.36M▲ 47.6% | -8.99M▼ 22.0% | -8.79M▲ 2.2% | -13.51M▼ 53.7% | -11.46M▲ 15.2% | -10.82M▲ 5.6% | -7.39M▲ 31.8% | -9.22M▼ 24.8% | -11.52M▲ 0% |
Operating Margin % | -93746.67% | -5336.23% | -42795.24% | - | - | - | - | - | - | - |
Operating Income Growth % | -55.98% | 47.63% | -22.04% | 2.16% | -53.66% | 15.17% | 5.57% | 31.75% | -24.81% | - |
EBITDA | -13.99M | -7.28M | -8.92M | -8.72M | -13.44M | -11.39M | -10.64M | -7.38M | -9.22M | -11.51M |
EBITDA Margin % | -93280% | -5277.54% | -42476.19% | - | - | - | - | - | - | - |
EBITDA Growth % | -56.13% | 47.95% | -22.48% | 2.23% | -54.06% | 15.22% | 6.59% | 30.59% | -24.81% | -66.87% |
D&A (Non-Cash Add-back) | 70K | 81K | 67K | 72K | 75K | 71K | 184K | 2K | 3K | 4.5K |
EBIT | -14.07M | -7.36M | -8.99M | -8.79M | -13.51M | -11.46M | -10.83M | -7.39M | -9.22M | -11.52M |
Net Interest Income | -1K | 0 | 0 | 0 | 0 | 0 | 0 | 231K | 0 | 280K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 231K | 0 | 280K |
Interest Expense | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -11K | 4K | 79K | -1K | 224K | -18K | -2K | 237K | 522K | 583K |
Pretax Income | -14.07M▲ 0% | -7.36M▲ 47.7% | -8.91M▼ 21.0% | -8.79M▲ 1.3% | -13.29M▼ 51.1% | -11.48M▲ 13.6% | -10.83M▲ 5.7% | -7.15M▲ 34.0% | -8.7M▼ 21.7% | -10.93M▲ 0% |
Pretax Margin % | -93820% | -5333.33% | -42419.05% | - | - | - | - | - | - | - |
Income Tax | -1.62M | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 11.52% | -0.05% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -12.45M▲ 0% | -7.36M▲ 40.9% | -8.91M▼ 21.0% | -8.79M▲ 1.3% | -13.29M▼ 51.1% | -11.48M▲ 13.6% | -10.83M▲ 5.7% | -7.15M▲ 34.0% | -8.7M▼ 21.7% | -10.93M▲ 0% |
Net Margin % | -83013.33% | -5333.33% | -42419.05% | - | - | - | - | - | - | - |
Net Income Growth % | -38.45% | 40.89% | -21.03% | 1.28% | -51.09% | 13.6% | 5.7% | 33.96% | -21.65% | -61.6% |
Net Income (Continuing) | -12.45M | -7.36M | -8.91M | -8.79M | -13.29M | -11.48M | -10.83M | -7.15M | -8.7M | -10.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -32801.22▲ 0% | -6218.35▲ 81.0% | -2074.18▲ 66.6% | -207.25▲ 90.0% | -111.32▲ 46.3% | -89.61▲ 19.5% | -46.76▲ 47.8% | -0.91▲ 98.1% | -1.45▼ 59.3% | -0.94▲ 0% |
EPS Growth % | 58.63% | 81.04% | 66.64% | 90.01% | 46.29% | 19.5% | 47.82% | 98.05% | -59.34% | 100% |
EPS (Basic) | -32801.22 | -6218.35 | -2074.18 | -207.25 | -111.32 | -89.61 | -46.87 | -0.91 | -1.45 | - |
Diluted Shares Outstanding | 380 | 1.18K | 4.26K | 42.43K | 118.68K | 126.16K | 231.51K | 787.47K | 5.98M | 11.62M |
Basic Shares Outstanding | 380 | 1.18K | 4.26K | 42.43K | 118.68K | 126.16K | 231K | 787.47K | 5.98M | 11.62M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PHIO Balance Sheet
Phio Pharmaceuticals Corp. (PHIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.83M | 15.15M | 7.3M | 15.16M | 24.73M | 12.45M | 9.32M | 5.74M | 21.48M | 17.4M |
Cash & Short-Term Investments | 3.58M | 14.88M | 6.93M | 14.24M | 24.06M | 11.78M | 8.49M | 5.38M | 21.03M | 17.03M |
Cash Only | 3.58M | 14.88M | 6.93M | 14.24M | 24.06M | 11.78M | 8.49M | 5.38M | 21.03M | 17.03M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 50K | 50K | 50K | 50K | 50K | 50K | 832K | 354K | 445K | 371K |
Total Non-Current Assets | 266K | 172K | 739K | 575K | 443K | 368K | 42K | 2K | 11K | 10K |
Property, Plant & Equipment | 248K | 172K | 721K | 557K | 416K | 344K | 39K | 2K | 11K | 10K |
Fixed Asset Turnover | 0.06x | 0.80x | 0.03x | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 18K | 0 | 18K | 18K | 27K | 24K | 3K | 0 | 0 | 0 |
Total Assets | 4.1M▲ 0% | 15.32M▲ 273.9% | 8.04M▼ 47.5% | 15.74M▲ 95.8% | 25.17M▲ 59.9% | 12.81M▼ 49.1% | 9.36M▼ 26.9% | 5.74M▼ 38.7% | 21.49M▲ 274.5% | 17.41M▲ 0% |
Asset Turnover | 0.00x | 0.01x | 0.00x | - | - | - | - | - | - | 0.00x |
Asset Growth % | -69.41% | 273.89% | -47.53% | 95.78% | 59.92% | -49.09% | -26.92% | -38.72% | 274.47% | 513.57% |
Total Current Liabilities | 2.27M | 1.74M | 1.88M | 2.2M | 3.07M | 1.94M | 1.63M | 1.01M | 435K | 260K |
Accounts Payable | 511K | 550K | 809K | 728K | 283K | 779K | 657K | 253K | 435K | 260K |
Days Payables Outstanding | 34.73 | 46.41 | - | 71.51 | 11.62 | 40.55 | 37.87 | 25.35 | - | 122.74 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 551K | 722K | 0 | 19K | 720K | 731K | -360K | 0 |
Current Ratio | 1.69x | 8.69x | 3.88x | 6.91x | 8.06x | 6.42x | 5.71x | 5.65x | 49.37x | 66.93x |
Quick Ratio | 1.69x | 8.69x | 3.88x | 6.91x | 8.06x | 6.42x | 5.71x | 5.65x | 49.37x | 66.93x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 411K | 526K | 170K | 35K | 0 | 0 | 905K | 690K |
Long-Term Debt | 0 | 0 | 0 | 231K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 411K | 295K | 170K | 35K | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 905K | 690K |
Total Liabilities | 2.27M | 1.74M | 2.29M | 2.72M | 3.24M | 1.97M | 1.63M | 1.01M | 1.34M | 950K |
Total Debt | 0 | 0 | 518K | 642K | 295K | 170K | 35K | 0 | 0 | 0 |
Net Debt | -3.58M | -14.88M | -6.42M | -13.6M | -23.76M | -11.61M | -8.46M | -5.38M | -21.03M | -17.03M |
Debt / Equity | - | - | 0.09x | 0.05x | 0.01x | 0.02x | 0.00x | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.48x |
Interest Coverage | -14073.00x | - | - | - | - | - | - | - | - | - |
Total Equity | 1.83M▲ 0% | 13.58M▲ 640.8% | 5.75M▼ 57.7% | 13.02M▲ 126.5% | 21.93M▲ 68.5% | 10.84M▼ 50.6% | 7.73M▼ 28.7% | 4.72M▼ 38.9% | 20.15M▲ 326.6% | 16.46M▲ 0% |
Equity Growth % | -83.11% | 640.75% | -57.67% | 126.46% | 68.49% | -50.57% | -28.69% | -38.9% | 326.57% | 628.33% |
Book Value per Share | 4828.51 | 11471.85 | 1348.54 | 306.77 | 184.79 | 85.92 | 33.39 | 6.00 | 3.37 | 1.42 |
Total Shareholders' Equity | 1.83M | 13.58M | 5.75M | 13.02M | 21.93M | 10.84M | 7.73M | 4.72M | 20.15M | 16.46M |
Common Stock | 0 | 2K | 1K | 1K | 0 | 0 | 0 | 0 | 1K | 1K |
Retained Earnings | -78.55M | -85.91M | -94.82M | -103.61M | -116.9M | -128.38M | -139.21M | -146.36M | -155.05M | -159.06M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -900K | -981K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHIO Cash Flow Statement
Phio Pharmaceuticals Corp. (PHIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.51M | -7.52M | -8.64M | -8.8M | -11.86M | -12.13M | -10.75M | -7.11M | -7.98M | -10.71M |
Operating CF Margin % | -63426.67% | -5449.28% | -41166.67% | - | - | - | - | - | - | - |
Operating CF Growth % | -22.6% | 20.96% | -14.96% | -1.82% | -34.72% | -2.29% | 11.38% | 33.84% | -12.19% | -315.3% |
Net Income | -12.45M | -7.36M | -8.91M | -8.79M | -13.29M | -11.48M | -10.83M | -7.15M | -8.7M | -10.93M |
Depreciation & Amortization | 70K | 81K | 67K | 72K | 75K | 193K | 184K | 35K | 3K | 4K |
Stock-Based Compensation | 314K | 282K | 300K | 136K | 480K | 414K | 303K | 147K | 481K | 164K |
Deferred Taxes | -1.62M | 0 | 0 | 0 | -233K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.71M | 405K | 109K | 111K | 117K | 0 | 126K | -6K | 0 | 589K |
Working Capital Changes | -530K | -523K | -213K | -327K | 990K | -1.26M | -536K | -138K | 235K | -532K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -608K | 39K | 259K | -81K | -445K | 496K | -122K | -404K | 183K | -166K |
Cash from Investing | -103K | -5K | -72K | -19K | -51K | -121K | -5K | 8K | -12K | -7K |
Capital Expenditures | -203K | -5K | -72K | -19K | -51K | -121K | -5K | -1K | -12K | -10K |
CapEx % of Revenue | 1353.33% | 3.62% | 342.86% | - | - | - | - | - | - | - |
Acquisitions | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 9K | 0 | 0 |
Cash from Financing | 292K | 18.82M | 772K | 16.13M | 21.72M | -26K | 7.41M | 4M | 23.64M | 14.47M |
Debt Issued (Net) | 0 | 0 | -6K | 204K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 292K | 18.82M | 709K | 12.07M | 19.58M | 2K | 7.44M | 4M | 23.67M | 14.5M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -15K | 0 | 0 | -11K | -1K | 0 | 0 |
Other Financing | 0 | 0 | 69K | 3.85M | 2.15M | -28K | -26K | -5K | -30K | -30K |
Net Change in Cash | -9.32M▲ 0% | 11.3M▲ 221.2% | -7.95M▼ 170.3% | 7.31M▲ 192.0% | 9.81M▲ 34.2% | -12.28M▼ 225.1% | -3.34M▲ 72.8% | -3.11M▲ 7.0% | 15.65M▲ 603.5% | 3.75M▲ 0% |
Free Cash Flow | -9.72M▲ 0% | -7.53M▲ 22.6% | -8.72M▼ 15.8% | -8.82M▼ 1.2% | -11.91M▼ 35.0% | -12.25M▼ 2.9% | -10.75M▲ 12.2% | -7.11M▲ 33.9% | -7.99M▼ 12.3% | -10.72M▲ 0% |
FCF Margin % | -64780% | -5452.9% | -41509.52% | - | - | - | - | - | - | - |
FCF Growth % | -25.15% | 22.56% | -15.84% | -1.19% | -35.01% | -2.86% | 12.21% | 33.86% | -12.34% | -68% |
FCF per Share | -25596.65 | -6357.76 | -2045.09 | -207.89 | -100.34 | -97.10 | -46.45 | -9.03 | -1.34 | -0.92 |
FCF Conversion (FCF/Net Income) | 0.76x | 1.02x | 0.97x | 1.00x | 0.89x | 1.06x | 0.99x | 0.99x | 0.92x | 0.98x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 11K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHIO Key Ratios
Phio Pharmaceuticals Corp. (PHIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -196.28% | -95.52% | -92.19% | -93.73% | -76.04% | -70.06% | -116.6% | -114.83% | -69.95% | -77.34% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 1151.88% |
Gross Margin | -35700% | -3034.78% | 100% | - | - | - | - | - | - | - |
Net Margin | -83013.33% | -5333.33% | -42419.05% | - | - | - | - | - | - | - |
Debt / Equity | - | - | 0.09x | 0.05x | 0.01x | 0.02x | 0.00x | - | - | 0.00x |
Interest Coverage | -14073.00x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 0.76x | 1.02x | 0.97x | 1.00x | 0.89x | 1.06x | 0.99x | 0.99x | 0.92x | 0.98x |
Revenue Growth | -21.05% | 820% | -84.78% | -100% | - | - | - | - | - | - |
Related:PHIO Dividend History·PHIO Revenue History·PHIO Price History·PHIO P/E History·PHIO Financial Ratios·PHIO Institutional Holders
PHIO SEC Filings & Documents
Phio Pharmaceuticals Corp. (PHIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
PHIO Frequently Asked Questions
Phio Pharmaceuticals Corp. (PHIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Phio Pharmaceuticals Corp. (PHIO) grew revenue by 0.0% over the past year. Growth has been modest.
Phio Pharmaceuticals Corp. (PHIO) reported a net loss of $10.9M for fiscal year 2025.
Dividend & Returns
Phio Pharmaceuticals Corp. (PHIO) has a return on equity (ROE) of -69.9%. Negative ROE indicates the company is unprofitable.
Phio Pharmaceuticals Corp. (PHIO) had negative free cash flow of $10.7M in fiscal year 2025, likely due to heavy capital investments.